T
Tagworks Pharmaceuticals
The development of therapeutics that can be released and activated selectively
About Tagworks Pharmaceuticals
Tagworks Pharmaceuticals is a biotech startup that operates in the oncology sector, developing innovative treatments for cancer patients. The company's primary technology is a controlled drug release system that is activated by an in vivo click reaction with a trigger molecule. This technology aims to enhance the therapeutic window and utility of potent systemic therapies, such as antibody-drug conjugates (ADCs) and immunomodulators.
Read full description
The company's unique approach allows for the on-target activation of these therapies in the tumor microenvironment, and the off-target deactivation of unwanted circulating radiopharmaceuticals. This is particularly beneficial in treating cancers that do not express suitable internalizing targets, which are the focus of conventional ADCs. Tagworks' lead program, TGW101, targets TAG72, a non-internalizing target found in solid tumors that has been largely inaccessible to current ADC therapies.
Tagworks Pharmaceuticals operates on a business model that involves securing funding for research and development, with the aim of bringing their innovative treatments to market. The company recently secured $65 million in Series A funding, which will be used to advance their clinical trials. Their primary clients are patients suffering from various types of cancer, and they operate in the global oncology market.
In summary, Tagworks Pharmaceuticals is a promising biotech startup with a unique approach to cancer treatment, backed by a seasoned team of researchers, oncologists, and biotech business builders.
At a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Nijmegen, Netherlands
- Employees
- 46
- Open positions
- 1
- Dealroom signal
- 83.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Drug Delivery Systems, Hard Tech, Woman Founder, Horizon Europe, DT and LS, science-based
- Technology
- Nanotech
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Tagworks Pharmaceuticals.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2023 | $65M | $260M | Lightstone Ventures · Meneldor · NEA · Oost NL - Eastern Netherlands Regional Development Agency | ↗ |
| SEEDOther financing | Sep 2021 | — | — | B.I.F. | — |
Growth signals
Latest recorded traffic for Tagworks Pharmaceuticals is 1.4K monthly website visits, up 7.7% over the last three months. Tagworks Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
B.I.F.
Series A7 investors entered at this stage
Ysios Capital
Gilde Healthcare
Lightstone Ventures
Meneldor
NEA
Oost NL - Eastern Netherlands Regional Development Agency
Novartis Venture Fund
Series B and later1 investor entered at this stage
Philips
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tagworks Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tagworks Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.